Less than 2 months after announcing a corporate restructuring, Neon Therapeutics has agreed to an acquisition by BioNTech for $67M in stock. The deal values $NTGN at $2.18 per share. The #cancer drug developer priced its 2018 IPO at $16 per share. https://xconomy.com/boston/2020/01/16/cancer-drug-developer-biontech-to-buy-neon-therapeutics-in-67m-deal/ … $BNTX
0 replies
2 proslijeđena tweeta
5 korisnika označava da im se sviđa
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.